Get the Stockscreener App
0.6029
3.89%
0.0226
Veru Inc stock is traded at $0.6029, with a volume of 408.30K.
It is up +3.89% in the last 24 hours and up +16.05% over the past month.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
See More
Previous Close:
$0.5803
Open:
$0.59
24h Volume:
408.30K
Relative Volume:
0.18
Market Cap:
$98.02M
Revenue:
$15.93M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.8039
EPS:
-0.75
Net Cash Flow:
$-59.50M
1W Performance:
-10.35%
1M Performance:
+16.05%
6M Performance:
-10.01%
1Y Performance:
-24.93%
1-Day Range:
$0.57
$0.6096
1-Week Range:
$0.5607
$0.6851
52-Week Range:
$0.45
$1.42
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
0.6029 | 98.02M | 15.93M | -64.59M | -59.50M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.64 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.87 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.17 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.24 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Investors Purchase High Volume of Put Options on Veru (NASDAQ:VERU) - Defense World
Traders Buy High Volume of Put Options on Veru (NASDAQ:VERU) - MarketBeat
Upward Trajectory: Veru Inc (VERU) Posts a Slidee, Closing at 0.60 - DWinneX
Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving AverageHere's Why - MarketBeat
Veru Inc. (NASDAQ:VERU) Stock Position Raised by Bank of America Corp DE - Defense World
VERU’s 2023 Market Dance: Up 6.22% – Time to Invest? - investchronicle.com
Veru to Participate in the Virtual BTIG Obesity Health Forum | V - GuruFocus
Veru to Participate in the Virtual BTIG Obesity Health Forum | VERU Stock News - GuruFocus
Veru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025 - Nasdaq
Veru to Participate in the Virtual BTIG Obesity Health Forum - The Manila Times
Veru Inc.'s (NASDAQ:VERU) 28% Share Price Surge Not Quite Adding Up - simplywall.st
Jane Street Group LLC Raises Stock Position in Veru Inc. (NASDAQ:VERU) - Defense World
VERUProspectus Filed Pursuant to Rule 424(b)(5) (424b5) - mx.advfn.com
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 - mx.advfn.com
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024 - mx.advfn.com
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter - mx.advfn.com
Is Veru Inc (NASDAQ: VERU) A Great Stock To Invest In? - Stocksregister
Cetera Investment Advisers Boosts Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - MSN
Veru Inc. (NASDAQ:VERU) Shares Sold by Northern Trust Corp - Defense World
Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leave - Seeking Alpha
Veru selects enobosarm 3mg dose for Phase 3 trials after positive study By Investing.com - Investing.com South Africa
Muscle-sparing obesity drug safe for Phase 3 trial, Veru says - BioPharma Dive
Veru selects enobosarm 3mg dose for Phase 3 trials after positive study - Investing.com Australia
Veru Reports Positive Safety Results From Phase 2B Quality Study - marketscreener.com
Veru Reports Positive Safety Results from Phase 2b QUALITY Study - GuruFocus
Veru (VERU) Advances Enobosarm in Clinical Trials with Promising - GuruFocus
Veru’s enobosarm shows increased fat loss, muscle preservation and safety - TipRanks
Veru, GameStop, Azul - TradingView
Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide - Nasdaq
Veru Reports Positive Safety Results from Phase 2b QUALITY - GlobeNewswire
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone - Yahoo Finance
Veru (VERU) Advances Enobosarm in Clinical Trials with Promising Safety Data | VERU Stock News - GuruFocus
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom - Seeking Alpha
B. Riley Forecasts Veru's Q4 Earnings (NASDAQ:VERU) - MarketBeat
B. Riley Analysts Decrease Earnings Estimates for Veru - Defense World
MPM Bioimpact LLC Acquires New Shares in Veru Inc. (NASDAQ:VERU) - MarketBeat
Veru Target of Unusually Large Options Trading (NASDAQ:VERU) - Defense World
Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial - MSN
Veru (NASDAQ:VERU) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Barclays PLC Acquires 21,738 Shares of Veru Inc. (NASDAQ:VERU) - Defense World
Veru Inc. (NASDAQ:VERU) Stake Raised by Wells Fargo & Company MN - Defense World
Veru Inc. (NASDAQ:VERU) Q2 2025 Earnings Call Transcript - Insider Monkey
Veru Inc. Reports Progress in Clinical Trials and Financials - TipRanks
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... - Yahoo Finance
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... By GuruFocus - Investing.com Canada
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
Earnings call transcript: Veru Inc. beats Q2 2025 EPS forecast, stock rises - Investing.com India
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress - GlobeNewswire
Veru Q2 2025 Earnings Call Transcript - MarketBeat
Veru Inc. Earnings Call: Promising Results Amid Challenges - TipRanks
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):